Freeline Hemophilia B Gene Therapy May Have Advantage Over Competitors
Almost No Patients Required Post-Treatment Factor Replacement Therapy
UniQure has a potential first-mover advantage, but Freeline study's investigator compares FLT180a to later model smartphones with bugs fixed.
You may also be interested in...
Unveiling its latest data, UniQure is tipped to avoid the knockback which affected BioMarin’s hemophilia A gene therapy, with a filing expected in the second half of 2021.
An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.